首页> 外文期刊>Yonsei Medical Journal >High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy
【24h】

High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy

机译:无法实时接受腔内近距离放射治疗的宫颈癌患者使用实时肿瘤跟踪放疗系统进行大剂量三维共形助推

获取原文
       

摘要

Purpose The purpose of this study is to evaluate the clinical results of treatment with a high dose of 3-dimensional conformal boost (3DCB) using a real-time tracking radiation therapy (RTRT) system in cervical cancer patients. Materials and Methods Between January 2001 and December 2004, 10 patients with cervical cancer were treated with a high dose 3DCB using RTRT system. Nine patients received whole pelvis radiation therapy (RT) with a median dose of 50 Gy (range, 40-50 Gy) before the 3DCB. The median dose of the 3DCB was 30 Gy (range, 25-30 Gy). Eight patients received the 3DCB twice a week with a daily fraction of 5 Gy. The determined endpoints were tumor response, overall survival, local failure free survival, and distant metastasis free survival. The duration of survival was calculated from the time of the start of radiotherapy. Results All patients were alive at the time of analysis and the median follow-up was 17.6 months (range, 4.9-27.3 months). Complete response was achieved in nine patients and one patient had a partial response. The 1- and 2-year local failure free survival was 78.8% and 54%, respectively. The 1- and 2-year distant metastasis free survival was 90% and 72%, respectively. Late toxicity of a grade 2 rectal hemorrhage was seen in one patient. A subcutaneous abscess was encountered in one patient. Conclusion The use of the high dose 3DCB in the treatment of cervical cancer is safe and feasible where intracavitary brachytherapy (ICBT) is unable to be performed. The escalation of the 3DCB dose is currently under evaluation.
机译:目的这项研究的目的是评估在宫颈癌患者中使用实时跟踪放射治疗(RTRT)系统以高剂量的3D共形增强(3DCB)治疗的临床结果。材料与方法2001年1月至2004年12月,采用RTRT系统对10例宫颈癌患者进行了大剂量3DCB治疗。 9名患者在3DCB之前接受了全骨盆放射治疗(RT),中位剂量为50 Gy(范围40-50 Gy)。 3DCB的中位剂量为30 Gy(范围25-30 Gy)。八名患者每周两次接受3DCB,每天一次5 Gy。确定的终点是肿瘤反应,总生存期,无局部衰竭生存期和无远处转移生存期。生存期从放疗开始算起。结果分析时所有患者均存活,中位随访时间为17.6个月(范围4.9-27.3个月)。 9名患者完全缓解,其中1名患者部分缓解。 1年和2年局部无故障生存率分别为78.8%和54%。 1年和2年远处无转移生存率分别为90%和72%。在一名患者中发现了2级直肠出血的晚期毒性。一名患者遇到皮下脓肿。结论在无法进行腔内近距离放射治疗(ICBT)的情况下,使用大剂量3DCB治疗宫颈癌是安全可行的。目前正在评估3DCB剂量的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号